Abstract: The present disclosure relates to thermoresponsive oil-in-water nanoemulsions that include: (a) one or more amphiphilic triblock copolymers; (b) one or more oils in the form of nanoemulsion droplets having an average size of about 20 nm to about 500 nm; (c) about 5 to about 40 wt. % of one or more surfactants; (d) one or more nonionic co¬ surfactants; and (e) water, wherein the nonemulsion undergoes a sol-to-gel transition at about 20° C. to about 50° C. One or more lipophilic active ingredients and/or one or more hydrophilic active ingredients may be incorporated into the nanoemulsions. The nanoemulsions are particularly useful for medical, pharmaceutical, and cosmetic applications.

Abstract: Compositions, methods, and systems for controlling crystallization of an agent are generally described. In some embodiments, an agent is crystallized in the presence of polymer matrices, such as polymer particles. The polymer matrix may influence at least a portion of the crystallization process and/or the resulting composition. In some such embodiments, the polymer matrix allows one or more aspect of the process and/or composition to be controlled and/or altered. For instance, the polymer matrix may act as a crystallization promoter and/or acceptable carriers of the crystallized agent. In certain embodiments, the polymer matrix described herein, can be used with any agent regardless of its chemical and/or physical properties.

Abstract: An emulsion-based method for the manufacture of a crystalized spherical agglomerate and/or a pharmaceutical product is provided; and crystalized spherical agglomerates and/or pharmaceutical products manufactured thereby.

Abstract: The invention concerns an emulsion-based method for the manufacture of a crystalized spherical agglomerate and/or a pharmaceutical product; and crystalized spherical agglomerate and/or a pharmaceutical product manufactured thereby.